Clinical trials: Cancer of the Esophagus
Esophageal Cancer
Adjuvant Radiotherapy for pT1b Esophageal Cancer After Submucosal Endoscopic Resection
Endoscopic Resection (ER) is a crucial therapeutic and diagnostic method for superficial esophageal cancer. However, lymph node metastasis rate in pT1b patients is relatively high.
- Trial name
- NCT05499195
- Where
- China
- Volunteers
- 159 people
- Sponsor
- Chinese Academy of Medical Sciences
Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung
Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura.
- Conditions
- Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma Breast Stage IV, Ovarian Cancer
- Trial name
- PITHAC (NCT06281860)
- Testing
- Cisplatine Teva®
- Where
- Switzerland
- Volunteers
- 39 people
- Sponsor
- Dr Jean Yannis PERENTES
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Esophageal Cancer
QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer
China bears a disproportionately high burden of esophageal cancer, accounting for approximately 50% of newly diagnosed cases worldwide, with an average 5-year survival rate of only 30%.
- Trial name
- BRICES (NCT07283991)
- Testing
- chemotherapy combined with Aparolitolovureli immunotherapy
- Volunteers
- 24 people
- Sponsor
- Ruijin Hospital
Esophageal Cancer
Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia
Hypothesis: In the management of advanced oesophageal cancer, to determine if a shorter regime of external beam radiotherapy (using higher daily doses, and combined with intraluminal high dose rate brachytherapy) is not inferior…
- Trial name
- NCT00665197
- Testing
- Protracted Course Radiotherapy, Short Course Radiotherapy
- Where
- 7 sites in Canada, China and 5 more
- Volunteers
- 200 people
- Sponsor
- International Atomic Energy Agency
Gastroesophageal Reflux Disease, Gastritis
Analysis of Biopsies From the Upper Gastrointestinal Tract
Multicenter study to correlate histological findings in the upper gastrointestinal tract with endoscopic and clinical data.
- Trial name
- histoGERD (NCT01576289)
- Testing
- Histological analysis
- Where
- Austria
- Volunteers
- 600 people
- Sponsor
- Medical University of Graz
Locally Advanced Esophageal Squamous Cell Carcinoma
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
- Trial name
- NCT03914443
- Testing
- Nivolumab, 5-FU, CDDP
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- National Cancer Center, Japan
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) with or without nivolumab to the effect of modified fluorouracil, leucovorin calcium, and…
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT05677490
- Testing
- Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 382 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage III Esophageal Squamous Cell Carcinoma, Stage II Esophageal Squamous Cell Carcinoma
Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer
A two-arm Phase III trial was started in Oct. 2014. Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the standard in Western countries in esophagus cancer.
- Trial name
- PFCRTESC (NCT02607540)
- Testing
- 2 cycles cisplatin-5-fluorouracil, 4 cycles cisplatin-5-fluorouracil, Radiotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Neoplasms, Stomach Neoplasms
Safety and Efficacy of Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Gastric-oesophageal Junction
The purpose of this study is to determine the dose limiting toxicity and the maximum tolerable dose of the radiochemotherapy with Docetaxel and Oxaliplatin in patients with adenocarcinoma of the gastric-oesophageal junction.
- Trial name
- NCT00374985
- Testing
- Docetaxel, Oxaliplatin, Radiotherapy
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Johannes Gutenberg University Mainz
Radiotherapy Side Effect, Chemotherapy Effect
Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）
To provide comprehensive efficacy and safety profiles of neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) versus surgery alone in resectable oesophageal carcinoma.
- Conditions
- Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs
- Trial name
- NCT04027543
- Testing
- Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy
- Where
- 3 sites in United States, China
- Volunteers
- 423 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Locally Advanced Oesophageal Cancer
Home Monitoring During Chemoradiation
Chemoradiotherapy is part of standard treatment for patients with locally advanced oesophageal cancer. Some patients with oesophageal cancer treated with chemoradiotherapy do not complete treatment due to toxicity, or face…
- Trial name
- AMCOR (NCT06597240)
- Testing
- AMCOR
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Locally Advanced Esophageal Squamous Cell Carcinoma
Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to learn if cadonilimab combined with anlotinib can be a safe and effective neoadjuvant therapy in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06426797
- Testing
- Cadonilimab plus anlotinib
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Esophageal Squamous Cell Carcinoma
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
This Phase II non-randomized study is to determine the efficacy and toxicity of neoadjuvant toripalimab plus chemotherapy followed by chemoradiotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
- Trial name
- NCT04844385
- Testing
- Toripalimab, Paclitaxel-albumin, Nedaplatin
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Gastrointestinal Cancer
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
This is Phase 1 dose finding trial with potential dose expansion to evaluate the safety, toxicity, recommended phase 2 dose (RP2D), and maximum tolerated dose (MTD) of Neratinib plus TDxD using a standard 3+3 dose escalation…
- Conditions
- Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
- Trial name
- NCT05274048
- Testing
- Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Fox Chase Cancer Center
Esophageal Neoplasms, Dysphagia
Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.
Esophageal cancer is the seventh most common type of cancer in the world, with an estimated global incidence of 604,100 new cases per year. The main symptom of esophageal cancer is dysphagia, associated or not with weight loss.
- Trial name
- NCT06070376
- Testing
- Fully Covered Esophageal Prosthesis (FC-SEMS), Partially Covered Esophageal Prosthesis (PC-SEMS)
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Esophageal Cancer, Neoantigen
Computational Prediction and Experimental Validation of Esophageal Cancer Associated Neoantigens
This study is to develop computational pipelines and experimental validation assays for improving the identification of neoantigens from patients with esophageal cancer.
- Trial name
- NCT05498168
- Testing
- ratio of predicted neoantigens
- Where
- Vietnam
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer
The study is intended to investigate the safety of BYL719 and AUY922 in patients with advanced gastric cancer, and to determine the MTD and/or RDE of both drugs in combination.
- Trial name
- NCT01613950
- Testing
- AUY922, BYL719
- Where
- 9 sites in United States, Germany and 4 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Esophageal Squamous Cell Carcinoma
Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma
Single arm phase II trial designed to assess the efficacy of durvalumab treatment in terms of 6-month progression-free survival.
- Trial name
- DESC (NCT04054518)
- Testing
- Durvalumab
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Tiago Biachi
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.